menu
    • menu
    [{"orgOrder":0,"company":"AnGes","sponsor":"Japan Agency for Medical Research and Development","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AG0302-COVID19","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AnGes \/ Japan Agency for Medical Research and Development","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Japan Agency for Medical Research and Development"},{"orgOrder":0,"company":"AnGes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AG0302-COVID-19","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AnGes \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Inapplicable"},{"orgOrder":0,"company":"AnGes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AMG0001","moa":"||VEGF-A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"AnGes \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnGes \/ Inapplicable"},{"orgOrder":0,"company":"AnGes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AG0302-COVID19","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AnGes \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Inapplicable"},{"orgOrder":0,"company":"AnGes","sponsor":"Japan Agency for Medical Research and Development","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AG0302-COVID19","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AnGes \/ Japan Agency for Medical Research and Development","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Japan Agency for Medical Research and Development"},{"orgOrder":0,"company":"AnGes","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"AG0302-COVID-19","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AnGes \/ Fresh Tracks Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Fresh Tracks Therapeutics"},{"orgOrder":0,"company":"AnGes","sponsor":"Vasomune Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AnGes \/ AnGes","highestDevelopmentStatusID":"8","companyTruncated":"AnGes \/ AnGes"},{"orgOrder":0,"company":"AnGes","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Lonafarnib","moa":"||Ftase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AnGes \/ AnGes","highestDevelopmentStatusID":"15","companyTruncated":"AnGes \/ AnGes"},{"orgOrder":0,"company":"AnGes","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"||Ftase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AnGes \/ AnGes","highestDevelopmentStatusID":"15","companyTruncated":"AnGes \/ AnGes"},{"orgOrder":0,"company":"AnGes","sponsor":"Erkim","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Beperminogene Perplasmid","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnGes \/ Erkim","highestDevelopmentStatusID":"15","companyTruncated":"AnGes \/ Erkim"},{"orgOrder":0,"company":"AnGes","sponsor":"Japan Agency for Medical Research and Development","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AG0301-COVID19","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnGes \/ Japan Agency for Medical Research and Development","highestDevelopmentStatusID":"7","companyTruncated":"AnGes \/ Japan Agency for Medical Research and Development"},{"orgOrder":0,"company":"AnGes","sponsor":"Emendo Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"EMD-101","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnGes \/ AnGes","highestDevelopmentStatusID":"4","companyTruncated":"AnGes \/ AnGes"},{"orgOrder":0,"company":"AnGes","sponsor":"Emendo Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Series B Financing","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnGes \/ AnGes","highestDevelopmentStatusID":"1","companyTruncated":"AnGes \/ AnGes"},{"orgOrder":0,"company":"AnGes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"||Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnGes \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AnGes \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by AnGes

    Menu

    AnGes

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vasculotide,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Recipient : Vasomune Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vasomune and AnGes Progress Phase 2a Trial Of AV-001 with High-Dose Cohort

                            Details : AV-001 is a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor is being investigated for the treatment of acute respiratory distress syndrome.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            December 03, 2024

                            Lead Product(s) : Vasculotide,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Recipient : Vasomune Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lonafarnib,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : Eiger BioPharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eiger and AnGes Receive Approval for Zokinvy® for Hutchinson-Gilford Progeria in Japan

                            Details : Zokinvy (lonafarnib) is a first-in-class farnesyltransferase inhibitor. It is approved for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies.

                            Product Name : Zokinvy

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 18, 2024

                            Lead Product(s) : Lonafarnib,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : Eiger BioPharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lonafarnib,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : Eiger BioPharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercializatio...

                            Details : Under the terms of the agreement, AnGes is responsible for obtaining and maintaining regulatory approval for Zokinvy (lonafarnib) in Japan and will be the exclusive partner for distribution and commercialization.

                            Product Name : Zokinvy

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 05, 2022

                            Lead Product(s) : Lonafarnib,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : Eiger BioPharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AG0302-COVID19,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Japan Agency for Medical Research and Development

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 06, 2021

                            Lead Product(s) : AG0302-COVID19,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Japan Agency for Medical Research and Development

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EMD-101,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Recipient : Emendo Biotherapeutics

                            Deal Size : $250.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            EmendoBio Gene Editing Company Acquired by AnGes, Inc.

                            Details : EmendoBio to operate as an independent subsidiary of AnGes with full access to AnGes’ global development resources to accelerate development and manufacturing capabilities for EmendoBio’s dual OMNI™ genome editing technology platforms.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 15, 2020

                            Lead Product(s) : EMD-101,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : Emendo Biotherapeutics

                            Deal Size : $250.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AG0302-COVID19,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Japan Agency for Medical Research and Development

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 07, 2020

                            Lead Product(s) : AG0302-COVID19,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Japan Agency for Medical Research and Development

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AG0302-COVID19,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of COVID-19 DNA Vaccine (AG0302-COVID19)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 26, 2020

                            Lead Product(s) : AG0302-COVID19,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AG0302-COVID-19,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Japan's AnGes Begins Phase 2/3 Clinical Trial Of DNA-Based COVID-19 Vaccine

                            Details : The trials involve 500 people. A group of 250 people will be vaccinated twice with AG0302-COVID19, in an interval of two weeks; the second group of 250 people twice with an interval of four weeks.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            August 12, 2020

                            Lead Product(s) : AG0302-COVID-19,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Beperminogene Perplasmid,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Erkim

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AnGes and Er-Kim Enter Into an Agreement for the Commercialization of Collategene® in Turkey

                            Details : Under the terms of the agreement, Er-Kim will have the exclusive rights to commercialize Collategene® in Turkey after obtaining the necessary regulatory approvals.

                            Product Name : Collategene

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 10, 2020

                            Lead Product(s) : Beperminogene Perplasmid,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Erkim

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AG0302-COVID-19,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Fresh Tracks Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AnGes Anoounces Collaboration Agreement with Brickell Biotech

                            Details : AnGes is currently conducting Phase 1/2 clinical studies with its vaccine candidate in Japan, and the results from these studies will guide AnGes’ and Brickell’s global development efforts of this novel vaccine candidate.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            August 09, 2020

                            Lead Product(s) : AG0302-COVID-19,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Fresh Tracks Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth